Global Information
회사소개 | 문의 | 위시리스트

뇌염 : 파이프라인 리뷰

Encephalitis - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 08월 상품 코드 465220
페이지 정보 영문 47 Pages
가격
US $ 2,000 ₩ 2,355,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,711,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,066,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


뇌염 : 파이프라인 리뷰 Encephalitis - Pipeline Review, H2 2019
발행일 : 2019년 08월 페이지 정보 : 영문 47 Pages

뇌염이란 뇌조직의 염증으로, 크게 1차성과 2차성의 2종류로 분류됩니다. 1차성 뇌염은 바이러스가 직접 뇌 및 척수에 감염하여 발병합니다. 2차성 뇌염은 신체의 다른 부위에 감염된 것이 뇌로 이동하여 발병합니다. 원인에는 일반적인 바이러스, 소아가 감염되는 바이러스, 아르보바이러스가 있습니다. 위험인자로 연령, 면역력 저하를 들 수 있습니다. 증상에는 열, 두통, 구토, 사경, 혼수 및 환각 등이 있습니다. 치료에는 진통제, 부신피질 스테로이드, 진경제, 진정제 등을 이용합니다.

뇌염 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 정리하여 전해드립니다.

서론

  • 조사 범위

뇌염;개요

치료제 개발

  • 파이프라인 제품;개요
  • 기업별 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Aeterna Zentaris Inc
  • CEL-SCI Corp
  • Prosetta Biosciences Inc
  • Sage Therapeutics Inc

약제 개요

  • 암포테리신 B 나트륨
  • CEL-1000
  • 밀테포신
  • PAV-645
  • 폐렴구균(23가) 백신
  • 급성 뇌염용 폴리글락틴 370
  • SAGE-718
  • 바이러스 감염증용 소분자
  • VY-OZ

휴지중인 프로젝트

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSA 17.03.22

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Encephalitis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Encephalitis - Pipeline by CEL-SCI Corp, H2 2019
  • Encephalitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Encephalitis - Pipeline by Knight Therapeutics Inc, H2 2019
  • Encephalitis - Pipeline by Sage Therapeutics Inc, H2 2019
  • Encephalitis - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Encephalitis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalitis - Pipeline Review, H2 2019, provides an overview of the Encephalitis (Central Nervous System) pipeline landscape.

Encephalitis is an inflammation of the brain tissue. There are two main types of encephalitis: primary and secondary. Primary encephalitis occurs when a virus directly infects the brain and spinal cord. Secondary encephalitis occurs when an infection starts elsewhere in the body and then travels to brain. Causes include common viruses, childhood viruses, and arboviruses. Risk factors include age and weak immune systems. Symptoms include fever, headache, vomiting, stiff neck, coma and hallucinations. Treatment includes pain killers, corticosteroids, anticonvulsants and sedatives.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 7 respectively.

Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Encephalitis (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Encephalitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Encephalitis - Overview
  • Encephalitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Encephalitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Encephalitis - Companies Involved in Therapeutics Development
    • CEL-SCI Corp
    • F. Hoffmann-La Roche Ltd
    • Knight Therapeutics Inc
    • Sage Therapeutics Inc
  • Encephalitis - Drug Profiles
    • Amphotericin B sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cerium dioxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • miltefosine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ocrelizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumococcal (13-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumococcal (23-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polyglactin 370 for Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAGE-718 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Encephalitis - Dormant Projects
  • Encephalitis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 06, 2018: Knight receives adverse notice of reassessment from CRA
      • Jun 28, 2017: FDA Grants Profounda Orphan Drug Designation for treatment of Granulomatous Amebic Encephalitis (GAE) with Miltefosine
      • Dec 17, 2016: Profounda receives FDA orphan-drug designation for the Treatment of Primary Amebic Meningoencephalitis (PAM) with Miltefosine
      • Aug 24, 2016: Orlando patient survives Primary Amebic Meningoencephalitis using Profoundas drug Impavido (miltefosine)
      • Dec 15, 2015: U.S. Issues Patent on Corifungin
      • Feb 26, 2013: National Institutes of Health Supports Acea's Research
      • Aug 22, 2011: Dr. James McKerrow, efficacy of Corifungin vs. Naegleria
      • Aug 22, 2011: FDA Grants 2nd Orphan drug designation
      • Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q